Ipsen Stock

Ipsen Equity

The The Equity of Ipsen (IPN.PA) as of Aug 8, 2026 is 4.34 B EUR. In the previous year, The Equity was 4.18 B EUR — a change of 3.69% (higher).

Equity

4.34 BEUR

YoY

3.69%

Last updated:

In 2026, Ipsen's equity was 4.34 B EUR, a 3.69% increase from the 4.18 B EUR equity in the previous year.

Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Ipsen's Equity

Ipsen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ipsen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ipsen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ipsen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ipsen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ipsen stock

The Equity of Ipsen is 4.34 B EUR in 2026.

The Equity of Ipsen changed from 4.18 B EUR to 4.34 B EUR, representing a 3.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Ipsen since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Ipsen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Ipsen

All Key Metrics — Ipsen